Henipavirus vaccine

Patent metadata

Field	Value
Publication number	US-11524066-B2
Application number	US-201716471541-A
Country	US
Kind code	B2
Filing date	Dec 22, 2017
Priority date	Dec 23, 2016
Publication date	Dec 13, 2022
Grant date	Dec 13, 2022

Abstract

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Henipavirus, particularly Hendra virus and/or Nipah virus or a disorder related to such an infection. In particular, the present invention concerns a Hendra virus and/or Nipah virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

First claim

The invention claimed is:

1. A method of treating or preventing a disorder, wherein the method comprises applying or administering to a subject in need thereof an effective amount of a composition comprising a RNA comprising at least one coding sequence encoding a Nipah virus fusion protein F:
(a) at least about 95% identical to the sequence of SEQ ID NO: 1 and wherein the Nipah virus fusion protein F is encoded by a RNA coding sequence at least about 95% identical to SEQ ID NO: 53; or
(b) at least about 95% identical to the sequence of SEQ ID NO: 573 and wherein the Nipah virus fusion protein F is encoded by a RNA coding sequence at least about 95% identical to SEQ ID NO: 625.

2. The method according to claim 1 , wherein the at least one coding sequence encodes a Nipah virus fusion protein F at least about 95% identical to the sequence of SEQ ID NO: 573.

3. The method according to claim 2 , wherein the at least one coding sequence encodes a Nipah virus fusion protein F identical to the sequence of SEQ ID NO: 573.

4. The method according to claim 1 , wherein the RNA encodes a Nipah virus fusion protein F identical or at least 95% identical to SEQ ID NO: 1.

5. The method according to claim 1 , wherein the RNA encodes at least one further protein element selected from a secretory signal peptide, a transmembrane domain, a VLP forming domain, a peptide linker, a self-cleaving peptide, an immunologic adjuvant sequence, and/or a dendritic cell targeting sequence.

6. The method according to claim 1 , wherein the RNA is bicistronic or multicistronic.

7. The method according to claim 1 , wherein the RNA is a mRNA.

8. The method according to claim 1 , wherein the G/C content of the at least one coding sequence is increased compared to the G/C content of the corresponding wild type coding sequence, and/or wherein the C content of the at least one coding sequence is increased compared to the C content of the corresponding wild type coding sequence and/or wherein the codons in the at least one coding sequence are adapted to human codon usage, wherein the codon adaptation index (CAI) is increased or maximised in the at least one coding sequence, wherein the amino acid sequence encoded by the at least one coding sequence is not modified compared to the amino acid sequence encoded by the corresponding wild type coding sequence.

9. The method according to claim 1 , wherein the RNA comprises an untranslated region (UTR).

10. The method according to claim 1 , comprising a plurality of RNA molecules encoding different antigenic protein.

11. The method according to claim 10 , wherein (i) each of the RNA molecules encodes a different antigenic protein derived from a Henipavirus and/or Hendra virus and/or Nipah virus; (ii) each of the RNA molecules encodes a different antigenic protein derived from genetically the same Henipavirus and/or Hendra virus and/or Nipah virus; or (iii) each of the RNA molecules encodes a different antigenic protein derived from a genetically different Henipavirus and/or Hendra virus and/or Nipah virus.

12. The method according to claim 1 , wherein RNA is complexed with one or more cationic or polycationic component.

13. The method according to claim 1 , wherein the artificial nucleic acid is complexed with one or more polysaccharides.

14. The method according to claim 1 , wherein the RNA is complexed with one or more lipids, thereby forming liposomes, lipid nanoparticles and/or lipoplexes.

15. The method according to claim 1 , wherein the composition comprises at least one adjuvant component.

16. The method according to claim 1 , wherein the RNA comprises in 5′ to 3′ direction, the following elements a)-g):
a) 5′-cap structure;
b) optionally, 5′-UTR element;
c) at least one coding sequence encoding the Nipah virus fusion protein F;
d) a 3′-UTR element;
e) optionally, poly(A) sequence;
f) optionally, poly(C) sequence; and
g) optionally, a histone stem-loop.

17. The method according to claim 16 , wherein the RNA comprises, in the 5′ to 3′ direction, the following elements a)-g):
a) 5′-cap structure;
b) a 5′-UTR element;
c) the at least one coding sequence encoding the Nipah virus fusion protein F;
d) a 3′-UTR element;
e) a poly(A) sequence;
f) optionally, poly(C) sequence; and
g) optionally, a histone stem-loop.

18. The method according to claim 12 , wherein the cationic or polycationic component is a cationic or polycationic polymer, a cationic or polycationic peptide or protein, or a cationic or polycationic lipid.

19. The method according to claim 12 , wherein the cationic or polycationic peptide or protein is a protamine.

Assignees

• CureVac SE

Inventors

• Jasny Edith
• Petsch Benjamin

Classifications

• C07K14/005

  from viruses · CPC title

• A61K2039/64

  characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units · CPC title

• A61K39/155 Primary

  Paramyxoviridae, e.g. parainfluenza virus · CPC title

• A61K2039/51

  comprising whole cells, viruses or DNA/RNA · CPC title

• C12N2760/18271

  Demonstrated in vivo effect · CPC title